Trial Profile
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Infigratinib (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 01 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.